{"title":"番茄红素对代谢综合征患者氧化应激和肝酶水平的调节作用：随机临床试验","authors":"Mahdi Mirahmadi, Malihe Aghasizadeh, Fatemeh Nazifkar, Mahla Ghafarian Choubdari, Reza Assaran-Darban, Shima Tavallaie, Hossein Hatamzadeh, Gordon Ferns, Mohammad Reza Mirinezhad, Hamed Baharara, Farzin Hadizadeh, Majid Ghayour-Mobarhan","doi":"10.22074/cellj.2023.2006158.1353","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The pathogenesis of metabolic syndrome (MetS) complications involves the excessive production of<br />reactive oxygen species, inflammation, and endothelial dysfunction. Due to Lycopene, a highly unstable structure and<br />its significant effects on modulating the metabolic system, there is a strong need for a formula that can increase its<br />stability. The aim of this study was to develop an approach for encapsulating Lycopene and investigate its effects on<br />inflammatory markers, oxidative stress, and liver enzymes in patients with MetS.<br />Materials and Methods: This study is a simple randomized, double-blind, objective-based clinical trial that involved<br />eighty subjects with MetS, who were equally and randomly assigned to two groups: one group received 20 mg of<br />Lycopene per day for 8 weeks, and the Placebo group followed the same protocol as the Lycopene group but received<br />a placebo instead of Lycopene. They were called Lycopene and placebo, respectively. During follow-up visits after 4<br />and 8 weeks, 20 ml of blood was collected for evaluation of liver enzymes and some inflammatory related markers.<br />Results: Prior to the assignment of volunteers to their respective groups, there were no notable differences in C-reactive<br />protein (CRP), serum liver enzymes, systolic and diastolic blood pressure, or pro-oxidant-antioxidant balance (PAB)<br />between the Lycopene and placebo groups. However, our subsequent analysis revealed a significant reduction in the<br />serum levels of CRP (P=0.001) and PAB (P=0.004) in the group that received Lycopene. Our encapsulated Lycopene<br />treatment was not associated with a significant difference in serum levels of alanine aminotransferase (ALT), aspartate<br />transferase (AST), or alkaline phosphatase (ALP) between our two groups.<br />Conclusion: This study investigated the impact of Lycopene on individuals with MetS, revealing a noteworthy<br />modulation effect on PAB and inflammation linked to MetS. However, no significant differences was demonstrated in<br />serum levels of ALT, AST and ALP between the studied group (registration number: IRCT20130507013263N3).</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10777315/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Effects of Lycopene on Modulating Oxidative Stress and Liver Enzymes Levels in Metabolic Syndrome Patients: A Randomised Clinical Trial.\",\"authors\":\"Mahdi Mirahmadi, Malihe Aghasizadeh, Fatemeh Nazifkar, Mahla Ghafarian Choubdari, Reza Assaran-Darban, Shima Tavallaie, Hossein Hatamzadeh, Gordon Ferns, Mohammad Reza Mirinezhad, Hamed Baharara, Farzin Hadizadeh, Majid Ghayour-Mobarhan\",\"doi\":\"10.22074/cellj.2023.2006158.1353\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The pathogenesis of metabolic syndrome (MetS) complications involves the excessive production of<br />reactive oxygen species, inflammation, and endothelial dysfunction. Due to Lycopene, a highly unstable structure and<br />its significant effects on modulating the metabolic system, there is a strong need for a formula that can increase its<br />stability. The aim of this study was to develop an approach for encapsulating Lycopene and investigate its effects on<br />inflammatory markers, oxidative stress, and liver enzymes in patients with MetS.<br />Materials and Methods: This study is a simple randomized, double-blind, objective-based clinical trial that involved<br />eighty subjects with MetS, who were equally and randomly assigned to two groups: one group received 20 mg of<br />Lycopene per day for 8 weeks, and the Placebo group followed the same protocol as the Lycopene group but received<br />a placebo instead of Lycopene. They were called Lycopene and placebo, respectively. During follow-up visits after 4<br />and 8 weeks, 20 ml of blood was collected for evaluation of liver enzymes and some inflammatory related markers.<br />Results: Prior to the assignment of volunteers to their respective groups, there were no notable differences in C-reactive<br />protein (CRP), serum liver enzymes, systolic and diastolic blood pressure, or pro-oxidant-antioxidant balance (PAB)<br />between the Lycopene and placebo groups. However, our subsequent analysis revealed a significant reduction in the<br />serum levels of CRP (P=0.001) and PAB (P=0.004) in the group that received Lycopene. Our encapsulated Lycopene<br />treatment was not associated with a significant difference in serum levels of alanine aminotransferase (ALT), aspartate<br />transferase (AST), or alkaline phosphatase (ALP) between our two groups.<br />Conclusion: This study investigated the impact of Lycopene on individuals with MetS, revealing a noteworthy<br />modulation effect on PAB and inflammation linked to MetS. However, no significant differences was demonstrated in<br />serum levels of ALT, AST and ALP between the studied group (registration number: IRCT20130507013263N3).</p>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2023-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10777315/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.22074/cellj.2023.2006158.1353\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.22074/cellj.2023.2006158.1353","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
The Effects of Lycopene on Modulating Oxidative Stress and Liver Enzymes Levels in Metabolic Syndrome Patients: A Randomised Clinical Trial.
Objective: The pathogenesis of metabolic syndrome (MetS) complications involves the excessive production of reactive oxygen species, inflammation, and endothelial dysfunction. Due to Lycopene, a highly unstable structure and its significant effects on modulating the metabolic system, there is a strong need for a formula that can increase its stability. The aim of this study was to develop an approach for encapsulating Lycopene and investigate its effects on inflammatory markers, oxidative stress, and liver enzymes in patients with MetS. Materials and Methods: This study is a simple randomized, double-blind, objective-based clinical trial that involved eighty subjects with MetS, who were equally and randomly assigned to two groups: one group received 20 mg of Lycopene per day for 8 weeks, and the Placebo group followed the same protocol as the Lycopene group but received a placebo instead of Lycopene. They were called Lycopene and placebo, respectively. During follow-up visits after 4 and 8 weeks, 20 ml of blood was collected for evaluation of liver enzymes and some inflammatory related markers. Results: Prior to the assignment of volunteers to their respective groups, there were no notable differences in C-reactive protein (CRP), serum liver enzymes, systolic and diastolic blood pressure, or pro-oxidant-antioxidant balance (PAB) between the Lycopene and placebo groups. However, our subsequent analysis revealed a significant reduction in the serum levels of CRP (P=0.001) and PAB (P=0.004) in the group that received Lycopene. Our encapsulated Lycopene treatment was not associated with a significant difference in serum levels of alanine aminotransferase (ALT), aspartate transferase (AST), or alkaline phosphatase (ALP) between our two groups. Conclusion: This study investigated the impact of Lycopene on individuals with MetS, revealing a noteworthy modulation effect on PAB and inflammation linked to MetS. However, no significant differences was demonstrated in serum levels of ALT, AST and ALP between the studied group (registration number: IRCT20130507013263N3).
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
